TDDS vs ODF: How to Choose the Right Film-Based Delivery Format
Share
Transdermal drug delivery systems (TDDS) and oral dissolving films (ODF) are often mentioned in the same breath — both are film-based dosage forms, both can be manufactured on continuous wet-coating platforms, and both represent alternatives to conventional solid oral dosage forms. For companies evaluating either format, or considering both, understanding where they converge and where they fundamentally diverge is essential for making the right product development and equipment investment decisions.
Huanghai manufactures continuous wet-coating platforms that support both ODF and transdermal patch production, including the MJ150 coating machine and MJF180 cutting and packaging system. The shared platform creates real efficiencies — but the products themselves serve different therapeutic purposes, face different regulatory requirements, and require different material architectures.
What ODF and TDDS Share: A Common Process Logic
The manufacturing process is where the two formats are most similar — and where a shared platform creates genuine value.
Both ODF and TDDS manufactured by wet-coating follow the same basic process sequence:
- Formulation: A drug-containing matrix is prepared as a fluid (solution, suspension, or gel)
- Coating: The fluid is applied onto a moving substrate at controlled thickness via a coating head
- Drying: The coated web passes through a temperature-controlled drying tunnel where water or solvent is removed
- Conversion: The dried web is laminated (TDDS) or left as-is (ODF), then slit and cut into individual units
Both formats share: - Continuous web processing (not batch) - The need for precise coating weight control - Sensitivity to drying conditions (temperature, airflow, residence time) - API uniformity requirements across the web - GMP cleanroom environment for pharmaceutical-grade production
Huanghai's MJ150 platform can support both ODF and TDDS production. Core modules are shared — however, switching between ODF and TDDS formats involves format-specific tooling changes and changeover operations that require Huanghai engineering support. In practice, most customers operate separate dedicated lines for ODF and TDDS.
Where ODF and TDDS Diverge: Delivery Route and Product Design Goals
Despite the manufacturing similarities, the two formats serve fundamentally different therapeutic purposes — and this drives differences in formulation strategy, material selection, regulatory pathway, and post-processing requirements.
Delivery Route and Absorption Barrier
| Dimension | ODF (Oral Dissolving Film) | TDDS (Transdermal Patch) |
|---|---|---|
| Delivery route | Oral — placed on tongue or buccal mucosa | Dermal — applied to skin surface |
| Primary absorption barrier | Oral mucosa / gastrointestinal tract | Stratum corneum (skin's outer layer) |
| Onset profile | Typically faster — dissolves in seconds to minutes | Slower onset — hours to reach therapeutic levels; sustained for hours to days |
| Duration of action | Single dose, short to medium duration | Extended — patches typically worn 24 hours to 7 days |
| First-pass metabolism | Can be bypassed if buccal/sublingual absorption occurs; otherwise subject to GI first-pass | Largely bypassed — systemic absorption via skin avoids hepatic first-pass |
| Target patient | Patients with dysphagia, pediatric, rapid onset needs | Patients requiring sustained systemic levels, chronic conditions, compliance-sensitive use |
| Best fit for | APIs suitable for oral/mucosal delivery; patient convenience for tablet replacement | APIs requiring sustained release; those poorly absorbed orally or with significant first-pass metabolism |
Formulation and Material Architecture
ODF formulations are designed to dissolve rapidly in the oral cavity, releasing the API for absorption through the mucosa or swallowing for GI absorption. The film matrix uses water-soluble polymers (e.g., HPMC, pullulan, PVA) with plasticizers and taste-masking agents. The primary design challenge is achieving rapid dissolution, palatability, and dose uniformity in a thin film format.
For a full overview of the certifications and compliance standards our equipment meets, see our Certifications & Compliance page.
TDDS formulations must achieve controlled API permeation across the skin barrier over an extended period. This requires: - Backing liner: Impermeable layer preventing API loss from the outer surface - Drug-containing matrix or reservoir: Engineered for controlled API release rate - Adhesive layer: Maintains skin contact throughout the wear period - Release liner: Peeled off before application
The material complexity is substantially higher in TDDS. The adhesive system must maintain skin contact for 24 hours to 7 days without causing irritation. Permeation enhancers are often required. The backing and release liner materials are selected for their barrier properties and compatibility with the drug matrix.
Regulatory Pathway and QC Requirements
Both formats are regulated as pharmaceutical drug products in most markets, but the specific requirements differ:
| Regulatory Element | ODF | TDDS |
|---|---|---|
| Key pharmacopoeial tests | Content uniformity, disintegration time, dissolution | Content uniformity, in vitro drug release (IVRT), adhesive performance |
| Bioequivalence standard | Standard oral BE or buccal absorption studies | In vitro-in vivo correlation (IVIVC) often required; BE studies specific to transdermal products |
| Stability testing | ICH conditions; packaging must prevent moisture uptake | ICH conditions; long-term skin adhesion performance included |
| Special considerations | Taste masking, polymer dissolution rate | Skin irritation testing, adhesive peel strength, cold flow resistance |
Post-Processing Differences
After drying, ODF processing involves: - Slitting the web to individual film dimensions - Cutting into unit doses - Packaging in unit-dose pouches (foil/foil or foil/transparent)
TDDS processing is more complex: - A backing liner must be laminated onto the dried drug matrix layer - The resulting composite web (backing / drug matrix / release liner) is then die-cut into patch shapes - Patch shapes may be square, round, or custom geometry - Individual patches are inserted into pouch packaging
The MJF180 automatic cutting and packaging system is designed primarily for ODF conversion. TDDS post-processing — particularly the backing liner lamination step and die-cutting — may require format-specific tooling or separate conversion equipment depending on the patch design.
Practical Decision Framework
Use the following criteria to determine which format better fits your project:
Choose ODF when: - The API is suitable for oral or mucosal absorption - Rapid onset is desired or required - The target patient population has difficulty swallowing conventional tablets - Product differentiation from tablets/capsules is a marketing objective - The regulatory pathway for oral drug products is better established for your API
Choose TDDS when: - The API requires sustained systemic delivery over hours to days - Oral bioavailability is limited by first-pass metabolism or GI instability - Patient compliance is a concern (once-daily or multi-day dosing preferred) - The API has established pharmacokinetic advantages via the transdermal route - The therapeutic indication requires steady-state plasma levels rather than peak-and-trough profiles
Consider both formats when: - You are developing a pipeline of film-based dosage forms and want platform flexibility - Your API candidates span both oral and transdermal applications - You want to offer both formats to different customer segments or markets
Huanghai's MJ150 platform — with its dual ODF/TDDS capability — is particularly relevant for companies building platform capacity rather than committing to a single format. The shared wet-coating and drying infrastructure reduces capital investment compared to acquiring separate dedicated lines.
Frequently Asked Questions
Q: Can the same coating machine produce both ODF and transdermal patches? A: Yes — this is one of the practical advantages of Huanghai's continuous wet-coating platform. The core coating and drying modules are compatible with both ODF and TDDS production. The primary differences are in post-coating processing: ODF requires simple slitting and cutting, while TDDS requires additional lamination of a backing liner and typically more complex die-cutting. Switching between formats on the MJ150 involves format-specific tooling changes that require Huanghai engineering support; in practice, most customers operate separate dedicated lines for each format. If dual-format capability on a single platform is a priority for your project, contact Huanghai to evaluate the configuration for your specific product requirements.
Q: Is ODF or TDDS more established in terms of regulatory approval pathways? A: Both are well-established in major pharmaceutical markets. ODF has a longer commercial track record as a dosage form replacement for tablets in pediatric and dysphagia applications. TDDS has equally well-established regulatory frameworks, particularly for pain management, smoking cessation, and hormone replacement — categories with numerous approved reference products. For new APIs, the choice of format depends on the pharmacokinetic profile of the drug rather than regulatory familiarity.
Q: Which format requires more complex formulation development? A: TDDS generally requires more complex formulation development than ODF. The primary challenge in ODF is achieving rapid dissolution and taste masking within a thin film. TDDS must additionally address skin permeation (a more difficult barrier than oral mucosa for most drugs), adhesive performance over the wear period, skin compatibility, and potentially permeation enhancement strategies. However, this complexity also means TDDS formulations tend to have higher barriers to competitive replication.
Q: What is the pilot-scale investment difference between ODF and TDDS? A: At the pilot scale, equipment requirements are similar. Huanghai's MJ150-L lab-scale coating machine at 8,000–10,000 films/hour supports both ODF and TDDS pilot production with the same process logic as the commercial platform. The incremental cost difference at pilot scale is primarily in post-coating tooling and materials (backing liner, die-cutting tools for TDDS vs. simpler slit-and-cut tooling for ODF). Commercial-scale investment considerations should be discussed based on specific project parameters.
Conclusion
TDDS and ODF share a manufacturing platform but serve distinctly different therapeutic purposes. The choice between them is primarily a product strategy decision — driven by the pharmacokinetics of your API, the clinical needs of your target patient population, and your regulatory pathway — not primarily an equipment decision.
For companies with the strategic flexibility to consider both formats, Huanghai's continuous wet-coating platform offers a practical path to building capacity that spans both product categories without requiring redundant capital investment.
Contact Huanghai to discuss your API profile, product strategy, and equipment configuration options for ODF, TDDS, or both.
Looking to build your own TDDS manufacturing line? Explore our Complete TDDS Manufacturing Solution — covering precision coating equipment, adhesive mixing systems, and die-cutting for transdermal patches.